Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quercetin dihydrate is a flavonoid small molecule and a specific hydrate form of quercetin, a naturally occurring polyphenolic compound found in various fruits, vegetables, and grains. It is developed and manufactured by Sichuan Lele Pharmaceutical Technology Development (also known as Sichuan Xieli Pharmaceutical) as part of their portfolio of rutin derivatives. Quercetin is widely recognized for its potent antioxidant, anti-inflammatory, and potential senolytic properties. Its mechanism of action involves scavenging reactive oxygen species (ROS) and inhibiting several key enzymes involved in inflammatory pathways, such as cyclooxygenase (COX) and lipoxygenase (LOX). Additionally, it has been shown to inhibit phosphoinositide 3-kinase (PI3K) and other signaling kinases, which may contribute to its anti-proliferative and cardiovascular protective effects. It is commonly used as a dietary supplement and is under investigation for various therapeutic applications, including cardiovascular health, metabolic disorders, and viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quercetin dihydrate.